soul trial oral semaglutide cardiovascular outcomes results 2024 nejm (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine SELECT Trial

Wipe the rubber stopper with an alcohol swab and let it air-dry for 30 seconds

Directions on how to use were very clear and I love that

Rapid weight loss Jennifer Hardy Jun 97 min read AstraZeneca Moves Toward the Oral GLP-1 Market with Elecoglipron The race to develop effective oral GLP-1 medications for obesity is heating up, and AstraZeneca is officially making its move

Sometimes a medication prescribed primarily for diabetes, but containing the same active ingredient as a weight loss drug, may be covered

You may experience symptoms of dumping syndrome

The trial evaluated once weekly cagrilintide doses in participants with overweight or obesity and reported dose dependent reductions in body weight at 26 weeks, with the paper describing the treatment as well tolerated in the study setting